Trial Profile
Evaluating the effects of the novel GLP1 analogue, Liraglutide, in patients with Alzheimer's Disease (ELAD study): a randomised, double-blind, placebo-controlled trial
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 03 Oct 2021
Price :
$35
*
At a glance
- Drugs Liraglutide (Primary)
- Indications Type 2 diabetes mellitus
- Focus Pharmacodynamics
- Acronyms ELAD
- 30 Jul 2021 Results presented at the Alzheimer's Association International Conference 2021
- 30 Jul 2021 Results presented at the Alzheimer's Association International Conference 2021
- 03 Jun 2021 According to ClinicalTrials.gov, the recruitment status of this study is unknown because the information has not been verified recently (last verified March 2019).